Automated Immunoassay Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[235+ Pages Report] According to Facts & Factors, the global automated immunoassay market size was estimated at USD 25.42 billion in 2025 and is expected to reach USD 82.85 billion by the end of 2034. The automated immunoassay industry is anticipated to grow by a CAGR of 14.06% between 2026 and 2034. The automated immunoassay Market is driven by increasing prevalence of chronic and infectious diseases coupled with rising demand for high-throughput automated diagnostic solutions.

Market Overview

The automated immunoassay market encompasses advanced analytical instruments and associated consumables designed to automate the detection and quantification of specific biomolecules through antigen-antibody interactions in biological samples such as blood, serum, plasma, or urine. These systems streamline laboratory workflows by handling sample incubation, reagent dispensing, washing, and signal detection with minimal human intervention, delivering rapid, reproducible, and highly sensitive results for applications ranging from disease diagnosis to therapeutic monitoring. Unlike manual methods, automated platforms support high-volume testing, reduce variability and errors, and integrate seamlessly with laboratory information systems, making them essential tools in modern clinical diagnostics, research, and pharmaceutical development where precision and efficiency are paramount.

Key Insights

• As per the analysis shared by our research analyst, the automated immunoassay market is anticipated to grow at a CAGR of 14.06% between 2026 and 2034.
• In terms of revenue, the market was valued at USD 25.42 billion in 2025 and is projected to reach USD 82.85 billion by 2034.
• The market is driven by the increasing prevalence of chronic and infectious diseases along with the rising adoption of automated laboratory solutions for efficient and accurate diagnostics.
• Based on the product segment, the chemiluminescence subsegment dominated the market with a 33% share because of its superior accuracy and sensitivity for low analyte concentrations.
• Based on the application segment, the infectious diseases subsegment dominated the market with a 30% share as it addresses urgent testing needs for pathogens in high-volume clinical environments.
• Based on the end-user segment, the hospitals subsegment dominated the market with a 35% share owing to advanced infrastructure and high patient testing volumes requiring reliable automation.
• Based on the region segment, North America dominated the market with a 35% share due to established healthcare systems, key industry presence, and high chronic disease burden.

Growth Drivers

• Rising prevalence of chronic and infectious diseases

The surge in chronic conditions such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders has intensified the need for frequent and precise biomarker testing, positioning automated immunoassay analyzers as critical tools for early detection and ongoing patient monitoring. These systems enable laboratories to process hundreds of samples per hour with consistent accuracy, directly supporting clinical decision-making and personalized treatment plans across diverse healthcare settings.

Technological integration, including chemiluminescence and fluorescence detection, further amplifies this demand by offering enhanced sensitivity and multiplexing capabilities that manual methods cannot match, thereby accelerating market expansion as healthcare providers prioritize efficiency and reliability in diagnostic workflows.

Restraints

• Shortage of skilled professionals and infrastructure limitations

Operation of sophisticated automated immunoassay platforms requires specialized training in calibration, maintenance, and data interpretation, yet many regions face acute shortages of qualified laboratory technicians and biomedical engineers. This skills gap delays adoption and increases operational costs for facilities transitioning from manual to automated systems.

In developing markets, inadequate healthcare infrastructure and limited access to reliable power or IT integration further hinder deployment, restricting the technology’s reach to only well-resourced urban hospitals and laboratories while slowing overall industry penetration.

Opportunities

• Technological advancements and AI integration

Emerging innovations such as AI-driven result interpretation, laser-based detection, and compact point-of-care analyzers are creating new avenues for faster, more accessible testing in non-traditional settings like clinics and remote areas. These developments promise improved sensitivity for low-abundance biomarkers and seamless connectivity with electronic health records.

Strategic collaborations between analyzer manufacturers and software developers are expected to unlock multiplexed testing platforms capable of simultaneous detection of multiple analytes, expanding applications into oncology, neurology, and infectious disease surveillance while driving long-term market growth.

Challenges

• High initial costs and availability of alternative technologies

The substantial capital investment required for fully automated systems, along with ongoing expenses for reagents and maintenance, poses a barrier for smaller laboratories and emerging economies seeking cost-effective diagnostic solutions.

Competition from semi-automated or alternative rapid testing methods that offer lower upfront costs can slow replacement cycles, requiring manufacturers to demonstrate clear return-on-investment through higher throughput and reduced error rates to maintain momentum.

Report Scope

Market Segmentation

The automated immunoassay market is segmented by product, application, end-user, and region.

Based on Product Segment, the automated immunoassay market is divided into chemiluminescence, immunofluorescence, enzyme linked fluorescent system, radioimmunoassay, and others. The chemiluminescence segment is the most dominant due to its exceptional sensitivity and ability to handle low concentrations of analytes effectively, enabling precise detection of hormones, proteins, and pathogens in clinical settings, which significantly drives market growth by supporting high-throughput testing in large laboratories and reducing diagnostic errors. The immunofluorescence segment stands as the second most dominant as it offers reliable quantitative results for a variety of conditions including infections and cancers, and its portability in point-of-care devices helps expand access in diverse healthcare environments, further propelling overall market expansion through innovation in rapid testing solutions.

Based on Application Segment, the automated immunoassay market is divided into infectious diseases, endocrinology, drug monitoring, chronic diseases, allergy testing, and others. The infectious diseases segment is the most dominant because of the persistent global burden of viral and bacterial pathogens requiring rapid, high-volume screening and monitoring, which automated platforms deliver with unmatched speed and reproducibility to support outbreak management and routine diagnostics. The chronic diseases segment stands as the second most dominant as rising incidences of cancer, diabetes, and cardiovascular conditions necessitate continuous biomarker tracking for treatment optimization, allowing these systems to enhance patient outcomes and drive sustained market demand through expanded clinical utility.

Based on End-User Segment, the automated immunoassay market is divided into hospitals, diagnostic laboratories, academic research institutes, biotech and pharma companies, and others. The hospitals segment is the most dominant owing to the concentration of high patient volumes, integrated care pathways, and availability of specialized staff that maximize the utilization of automated platforms for immediate diagnostic support across emergency, inpatient, and outpatient services. The diagnostic laboratories segment stands as the second most dominant because of their focus on high-throughput batch processing and reference testing services, enabling economies of scale and faster turnaround times that attract partnerships with healthcare networks and further accelerate market growth.

Recent Developments

• In June 2023, EUROIMMUN launched the UNIQO 160 automated indirect immunofluorescence test system featuring integrated image analysis, slide washing, and sample preparation capabilities, significantly enhancing efficiency for autoimmune disease diagnostics while securing CE mark compliance for broader European adoption.
• In March 2023, bioMérieux completed a strategic investment in Proxim Diagnostics to accelerate the launch of a fully automated, mobile immunodiagnostic platform using disposable cartridges for multiplexed testing, targeting point-of-care and emergency settings with rapid results.
• In February 2023, Epitope Diagnostics released a comprehensive panel of chemiluminescence immunoassay kits paired with fully automated ECL25 and ECL100 analyzers, expanding testing options across multiple clinical domains and improving accessibility for medium-sized laboratories.
• In July 2023, Anbio Biotechnology introduced the compact AF-100S fluorescent immunoassay analyzer designed for affordable, rapid, and accurate clinical diagnostics, addressing the need for portable solutions in resource-limited environments while maintaining high performance standards.

Regional Analysis

• North America to dominate the global market

North America maintains its leading position through a combination of advanced healthcare infrastructure, widespread adoption of laboratory automation, and the presence of major industry players headquartered in the region. The United States serves as the primary growth engine, benefiting from high healthcare expenditure, extensive diagnostic networks, and strong regulatory frameworks that encourage innovation in immunoassay technologies. Rising geriatric populations and increasing incidence of chronic conditions further stimulate demand for high-throughput analyzers in both hospital and reference laboratory settings. Collaborative research initiatives between academic institutions and manufacturers continue to refine assay performance, solidifying the region’s technological edge.

Europe demonstrates robust growth supported by universal healthcare systems and stringent quality standards that prioritize accurate diagnostics. Countries such as Germany and the United Kingdom lead through well-funded public health programs and established clinical laboratory chains that rapidly integrate new automated platforms. Focus on early disease detection and personalized medicine drives consistent investment in chemiluminescence and fluorescence-based systems across major urban centers. Cross-border collaborations and EU-wide standardization efforts facilitate smoother technology adoption while addressing regulatory harmonization.

Asia Pacific emerges as the fastest-expanding region fueled by rising healthcare investments, expanding middle-class populations, and government initiatives aimed at modernizing diagnostic infrastructure. China and India dominate through large patient bases and increasing numbers of hospitals and independent laboratories adopting automated solutions to handle growing testing volumes. Rapid urbanization and improved access to advanced care in tier-1 cities accelerate replacement of manual methods with high-throughput analyzers. Local manufacturers are also entering the market with cost-effective platforms tailored to regional needs.

Latin America shows steady progress driven by improving healthcare access and rising awareness of preventive diagnostics in countries such as Brazil and Mexico. Public-private partnerships are expanding laboratory networks while international manufacturers establish local distribution and service centers to support adoption. Focus on infectious disease control programs continues to boost demand for reliable automated immunoassay systems in both urban and rural facilities.

The Middle East & Africa region is gradually building momentum through targeted healthcare modernization projects and increasing foreign investment in diagnostic capabilities. Leading markets such as Saudi Arabia and South Africa are investing in advanced laboratory infrastructure to address chronic disease burdens and improve outbreak preparedness. Although challenges related to infrastructure and skilled workforce remain, growing partnerships with global technology providers are introducing automated platforms that enhance testing accuracy and efficiency across the region.

Competitive Analysis

The global automated immunoassay market is dominated by players:

• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Siemens Healthineers
• Danaher Corporation
• bioMérieux SA
• Sysmex Corporation
• PerkinElmer Inc.
• others

The global automated immunoassay market is segmented as follows:

By Product

• Chemiluminescence
• Immunofluorescence
• Enzyme Linked Fluorescent System
• Radioimmunoassay
• Others

By Application

• Infectious Diseases
• Endocrinology
• Drug Monitoring
• Chronic Diseases
• Allergy Testing
• Others

By End-User

• Hospitals
• Diagnostic Laboratories
• Academic Research Institutes
• Biotech and Pharma Companies
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America